References
Schulman, K.A. & Tunis, S.R. Nat. Biotechnol. 28, 1157–1159 (2010).
Meckley, L.M. & Neumann, P.J. Health Policy 94, 91–100 (2010).
Trosman, J.R., Van Bebber, S.L. & Phillips, K.A. J. Oncol. Pract. 6, 238–242 (2010).
Anonymous. The New Science of Personalized Medicine: Translating the Promise into Practice (PricewaterhouseCoopers, 2009).
Mohr, P.E. & Tunis, S.R. Pharmacoeconomics 28, 153–162 (2010).
Tunis, S.R. & Pearson, S.D. Health Aff. 25, 1218–1230 (2006).
Atkinson, W. The impact of CED on private payers. Biotechnology Healthcare 24–30 (April 2007).
Kaiser Family Foundation. Kaiser Slides: Medicare Enrolment, 1966–2010 <http://facts.kff.org/chart.aspx?ch=1714> (Accessed 26 January 2011).
Filmore, D. & Bylander, J. The Gray Sheet (28 June 2010).
PricewaterhouseCoopers. Diagnostics 2009: Moving Towards Personalised Medicine (PricewaterhouseCoopers, 2009).
The Lewin Group. The Value of Diagnostics Innovation, Adoption and Diffusion into Health Care (The Lewin Group, 2005).
Allison, M. Nat. Biotechnol. 26, 509–517 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.N.M. presently works for GlaxoSmithKline, but the correspondence is based on work done at the University of Cambridge.
Rights and permissions
About this article
Cite this article
Malik, N. Overhauling the reimbursement system for molecular diagnostics. Nat Biotechnol 29, 390–391 (2011). https://doi.org/10.1038/nbt.1869
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1869
- Springer Nature America, Inc.
This article is cited by
-
Biomarker patents for diagnostics: problem or solution?
Nature Biotechnology (2012)